Skip to content

Home
Product
Team
News
Career
Contact

Home Press Release

Media Folder: Press Release

Sorry, no results were found.

Search for:

Search

Articles récents

Enjoy visiting our new website !
Bio-Europe Spring 2026
NX210c Demonstrates Therapeutic Potential to Restore Blood–Brain Barrier in a QSP Model of Relapsing–Remitting Multiple Sclerosis
Healthcare Days JP Morgan Week 2026
SEALS Second DSMB Positive Review

Commentaires récents

No comments to show.

Axoltis 
60 avenue Rockefeller, 69008 Lyon, France

© 2026 Axoltis. All rights reserved. Disclaimer : NX210c is a drug candidate currently in a Phase 2 clinical trial for ALS and is not yet approved for commercialization.

Legal Notice